For research use only. Not for therapeutic Use.
NBDHEX（Cat No.:I017327）is a potent inhibitor of glutathione S-transferase P1-1 (GSTP1-1), an enzyme often overexpressed in cancer cells, where it aids in detoxifying chemotherapy agents and supports cancer cell survival. By targeting GSTP1-1, NBDHEX disrupts the cell’s defense against oxidative stress, leading to apoptosis in tumor cells. Additionally, it induces oxidative damage selectively in cancer cells, enhancing its therapeutic potential. NBDHEX’s role in overcoming drug resistance has made it a valuable candidate in cancer research, particularly in exploring new strategies for tumors that are resistant to standard treatments.
| Catalog Number | I017327 |
| CAS Number | 787634-60-0 |
| Molecular Formula | C₁₂H₁₅N₃O₄S |
| Purity | ≥95% |
| Target | Autophagy |
| IUPAC Name | 6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexan-1-ol |
| InChI | InChI=1S/C12H15N3O4S/c16-7-3-1-2-4-8-20-10-6-5-9(15(17)18)11-12(10)14-19-13-11/h5-6,16H,1-4,7-8H2 |
| InChIKey | RGXYYAZGELLKDA-UHFFFAOYSA-N |
| SMILES | C1=C(C2=NON=C2C(=C1)SCCCCCCO)[N+](=O)[O-] |
| Reference | [1]. Sha HH, et al. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound. Biosci Rep. 2018 Feb 13;38(1). pii: BSR20171440.<br>[2]. Filomeni G, et al. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther. 2008 Feb;7(2):371-9.<br>[3]. Pellizzari Tregno F, et al. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer. 2009 Sep;45(14):2606-17. |
